Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and-5

被引：7

作者：

Dan, A ^{[1
]}

Shiyama, T ^{[1
]}

Yamazaki, K ^{[1
]}

Kusunose, N ^{[1
]}

Fujita, K ^{[1
]}

Sato, H ^{[1
]}

Matsui, K ^{[1
]}

Kitano, M ^{[1
]}

机构：

[1] Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 18期

关键词：

phosphodiesterase;

D O I：

10.1016/j.bmcl.2005.06.016

中图分类号：

R914 [药物化学];

学科分类号：

100701 [药物化学];

摘要：

HTS and the following synthesis of a series of the compounds led us to the discovery of hydroxamic acid analogs as potent dual inhibitors of phosphodiesterase (PDE)-1 and 5. These compounds have highly related structure and deviation of the structure usually resulted in reduced potency. This result can be used to design other molecules that may be utilized for the therapy of cardiovascular symptoms that relates to cGMP level. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：4085 / 4090

页数：6

共 6 条

[1]

CHARACTERIZATION OF A NOVEL POTENT AND SPECIFIC INHIBITOR OF TYPE-V PHOSPHODIESTERASE [J].

COSTE, H ;

GRONDIN, P .

BIOCHEMICAL PHARMACOLOGY, 1995, 50 (10) :1577-1585

[2]

Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: In vitro and in vivo characterization [J].

Delpy, E ;

deGouville, ACL .

BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) :1377-1384

[3]

A TFA-cleavable linkage for solid-phase synthesis of hydroxamic acids [J].

Richter, LS ;

Desai, MC .

TETRAHEDRON LETTERS, 1997, 38 (03) :321-322

[4]

Cyclic GMP phosphodiesterases and regulation of smooth muscle function [J].

Rybalkin, SD ;

Yan, C ;

Bornfeldt, KE ;

Beavo, JA .

CIRCULATION RESEARCH, 2003, 93 (04) :280-291

[5]

Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor [J].

Vemulapalli, S ;

Watkins, RW ;

Chintala, M ;

Davis, H ;

Ahn, HS ;

Fawzi, A ;

Tulshian, D ;

Chiu, P ;

Chatterjee, M ;

Lin, CC ;

Sybertz, EJ .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (06) :862-869

[6]

Wallis RM, 1999, AM J CARDIOL, V83, p3C

← 1 →